GSK (LON:GSK) Insider Julie Brown Buys 7 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown acquired 7 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were purchased at an average price of GBX 1,803 per share, with a total value of £126.21.

GSK Trading Down 0.3%

GSK stock traded down GBX 5 during midday trading on Friday, reaching GBX 1,770.50. 922,420,813 shares of the company’s stock traded hands, compared to its average volume of 13,290,600. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. GSK plc has a fifty-two week low of GBX 1,455 and a fifty-two week high of GBX 2,282. The business has a 50-day moving average price of GBX 1,906.66 and a two-hundred day moving average price of GBX 1,969.53. The company has a market capitalization of £70.94 billion, a P/E ratio of 15.03, a PEG ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last posted its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Equities research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research note on Wednesday, September 2nd. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,975 target price on shares of GSK in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, GSK presently has an average rating of “Hold” and an average target price of GBX 2,039.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.